The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2021 | Myeloma: BCMA loss as an escape mechanism
B-cell maturation antigen (BCMA) has become a widely used therapeutic target in multiple myeloma, with three major forms of treatment including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. In this video, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on BCMA loss as an escape mechanism. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
